검색어 : 통합검색[Partridge Ian]
총 174건 중 174건 출력
, 13/18 페이지
-
121
- Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer
- O'Sullivan, Ciara C; Ballman, Karla V; McCall, Linda; Kommalapati, Anuhya; Zemla, Tyler; Weiss, Anna; Mitchell, Melissa; Blinder, Victoria; Tung, Nadine M; Irvin, William J; Lee, Myounghee; Goetz, Matthew P; Symmans, William Fraser; Borges, Virginia F; Krop, Ian; Carey, Lisa A; Partridge, Ann H; Department of Oncology,Mayo Clinic, Rochester, MN 55905, USA; Alliance Statistics & Data Center,Weil Cornell Medicine, NY 10065, USA; Alliance Statistics & Data Center,Duke University, Durham, NC 27708, USA; Department of Oncology,Mayo Clinic, Rochester, MN 55905, USA; Alliance Statistics & Data Center,Mayo Clinic, Rochester, MN 55905, USA; Division of Breast Surgery,Department of Surgery,Brigham & Women's Hospital, Boston, MA 02115, USA; Department of Radiation Oncology,University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Psychiatry & Behavioral Sciences,Breast Medicine Service,Memorial Sloan Kettering Cancer Center, NY 10065, USA; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Department of Medical Oncology,Bon Secours Cancer Institute, Midlothian, VA, USA; Department of Pharmacy,University of Maryland Medical Center, Baltimore, MD, USA; Department of Oncology,Mayo Clinic, Rochester, MN 55905, USA; Department of Pathology,Univ; (Future oncology, v.17, 2021, pp.4665-4676)
-
122
- Atlas of the aging mouse brain reveals white matter as vulnerable foci
- Hahn, Oliver; Foltz, Aulden G.; Atkins, Micaiah; Kedir, Blen; Moran-Losada, Patricia; Guldner, Ian H.; Munson, Christy; Kern, Fabian; Pá lovics, Ró bert; Lu, Nannan; Zhang, Hui; Kaur, Achint; Hull, Jacob; Huguenard, John R.; Grö nke, Sebastian; Lehallier, Benoit; Partridge, Linda; Keller, Andreas; Wyss-Coray, Tony; ; (Cell, v.186, 2023, pp.4117-4133.e22)
-
123
- A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
- O'Sullivan, Ciara Catherine Maria; Ballman, Karla V.; McCall, Linda Mackie; Zemla, Tyler J.; Weiss, Anna; Mitchell, Melissa; Blinder, Victoria Susana; Tung, Nadine M.; Irvin, William Johnson; Lee, Myounghee; Goetz, Matthew P.; Symmans, William Fraser; Borges, Virginia F.; Krop, Ian E.; Partridge, Ann H.; Carey, Lisa A.; NCI/NIH, Bethesda, MD; ; Weill Cornell Medicine, New York, NY; ; Alliance for Clinical Trials in Oncology, Durham, NC; ; Mayo Clinic, Rochester, MN; ; The University of Texas MD Anderson Cancer Center, Houston, TX; ; University of Texas MD Anderson Cancer Center, Houston, TX; ; Memorial Sloan Kettering Cancer Center, New York, NY; ; Beth Israel Deaconess Medical Center, Boston, MA; ; University of North Carolina, Midlothian, VA; ; University of Maryland Medical Center, Baltimore, MD; ; Mayo Clinic, Rochester, MN; ; The University of Texas MD Anderson Cancer Center, Houston, TX; ; University of Colorado, Aurora, CO; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; University of North Carolina, Chapel Hill, NC; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.39, 2021, pp.TPS595-TPS595)
-
124
- Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
- Lipsyc-Sharf, Marla; de Bruin, Elza C.; Santos, Katheryn; McEwen, Robert; Stetson, Daniel; Patel, Ashka; Kirkner, Gregory J.; Hughes, Melissa E.; Tolaney, Sara M.; Partridge, Ann H.; Krop, Ian E.; Knape, Charlene; Feger, Ute; Marsico, Giovanni; Howarth, Karen; Winer, Eric P.; Lin, Nancy U.; Parsons, Heather A.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Cambridge, United Kingdom; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Cambridge, United Kingdom; AstraZeneca, Waltham, MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Inivata Inc, Research Triangle Park, NC; Inivata Inc, Research Triangle Park, NC; Inivata Ltd, Cambridge, United Kingdom; Inivata Ltd, Cambridge, United Kingdom; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.40, 2022, pp.2408-2419)
-
125
- Physical and Chemical Properties of Cloud Droplet Residuals and Aerosol Particles During the Arctic Ocean 2018 Expedition
- Karlsson, Linn; Baccarini, Andrea; Duplessis, Patrick; Baumgardner, Darrel; Brooks, Ian M.; Chang, Rachel Y.‐ W.; Dada, Lubna; Dä llenbach, Kaspar R.; Heikkinen, Liine; Krejci, Radovan; Leaitch, W. Richard; Leck, Caroline; Partridge, Daniel G.; Salter, Matthew E.; Wernli, Heini; Wheeler, Michael J.; Schmale, Julia; Zieger, Paul; Department of Environmental Science Stockholm University Stockholm Sweden; Extreme Environments Research Laboratory É cole Polytechnique fé dé rale de Lausanne Sion Switzerland; Department of Physics and Atmospheric Science Dalhousie University Halifax NS Canada; Droplet Measurement Technologies LLC Boulder CO USA; Institute for Climate and Atmospheric Science School of Earth and Environment University of Leeds Leeds UK; Department of Physics and Atmospheric Science Dalhousie University Halifax NS Canada; Extreme Environments Research Laboratory É cole Polytechnique fé dé rale de Lausanne Sion Switzerland; Laboratory of Atmospheric Chemistry Paul Scherrer Institute Villigen Switzerland; Department of Environmental Science; (Journal of geophysical research. Atmospheres, v.127, 2022, pp.e2021JD036383)
-
126
- Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
- Fernandez-Martinez, Aranzazu; Krop, Ian E.; Hillman, David W.; Polley, Mei-Yin; Parker, Joel S.; Huebner, Lucas; Hoadley, Katherine A.; Shepherd, Jonathan; Tolaney, Sara; Henry, N. Lynn; Dang, Chau; Harris, Lyndsay; Berry, Donald; Hahn, Olwen; Hudis, Clifford; Winer, Eric; Partridge, Ann; Perou, Charles M.; Carey, Lisa A.; Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC; Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA; University of Michigan Rogel Cancer Center, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY; National Cancer Institute, Cancer Diagnostics Program, Bethesda, MD; Division of Biostatistics, MD Anderson Cancer Center, Houston, TX; Alliance Protocol Operations Office, University of Chicago, Chicago,; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.38, 2020, pp.4184-4193)
-
127
- Abstract PD3-05: The DAPHNE trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer
- Waks, Adrienne G.; Desai, Neelam V.; Li, Tianyu; Poorvu, Philip D.; Partridge, Ann H.; Sinclair, Natalie; Spring, Laura M.; Faggen, Meredith; Constantine, Michael; Alberti, Jillian C.; Deane, Julia; Rosenberg, Shoshana M.; Tolaney, Sara M.; Krop, Ian E.; Tung, Nadine M.; Tayob, Nabihah; King, Tari A.; Mittendorf, Elizabeth A.; Winer, Eric P.; ; (Cancer research : the official organ of the American Association for Cancer Research, Inc, v.81, 2021, pp.PD3-05-PD3-05)
-
128
- Progress Toward Poliovirus Containment Implementation — Worldwide, 2018–2019
- Moffett, Daphne B.; Llewellyn, Anna; Singh, Harpal; Saxentoff, Eugene; Partridge, Jeffrey; Iakovenko, Maria; Roesel, Sigrun; Asghar, Humayun; Baig, Najam; Grabovac, Varja; Gurung, Santosh; Gumede-Moeletsi, Nicksy; Barnor, Jacob; Theo, Andros; Rey-Benito, Gloria; Villalobos, Andrea; Boualam, Liliane; Swan, Joseph; Sutter, Roland W.; Pandel, Ekkehart; Wassilak, Steven; Oberste, M. Steven; Lewis, Ian; Zaffran, Michel; ; (Morbidity and mortality weekly report : MMWR, v.68, 2019, pp.825-829)
-
129
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
- Tolaney, Sara M.; Barry, William T.; Dang, Chau T.; Yardley, Denise A.; Moy, Beverly; Marcom, P. Kelly; Albain, Kathy S.; Rugo, Hope S.; Ellis, Matthew; Shapira, Iuliana; Wolff, Antonio C.; Carey, Lisa A.; Overmoyer, Beth A.; Partridge, Ann H.; Guo, Hao; Hudis, Clifford A.; Krop, Ian E.; Burstein, Harold J.; Winer, Eric P.; ; (The New England journal of medicine, v.372, 2015, pp.134-141)
-
130
- Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
- Bellon, Jennifer R.; Guo, Hao; Barry, William T.; Dang, Chau T.; Yardley, Denise A.; Moy, Beverly; Marcom, P. Kelly; Albain, Kathy S.; Rugo, Hope S.; Ellis, Matthew; Wolff, Antonio C.; Carey, Lisa A.; Overmoyer, Beth A.; Partridge, Ann H.; Hudis, Clifford A.; Krop, Ian; Burstein, Harold J.; Winer, Eric P.; Tolaney, Sara M.; ; (Breast cancer research and treatment, v.176, 2019, pp.303-310)
QUICK MENU
